Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PMCC-COE-KMA in Relapsed/Refractory Multiple Myeloma
NCT07541391Phase 1Recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- May 2026
- Primary completion
- Sep 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KMA.CAR-T in multiple myeloma (MM), sponsored by Peter MacCallum Cancer Centre. Primary endpoints: Maximum Tolerated Dose at 28 days and Manufacturing Feasibility at 28 days. Started May 2026; status: recruiting.
02
Drugs
KMA.CAR-T
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07541391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07541391.